Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

231
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
231
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

271
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
271
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

408
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
408
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

274
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
274
Data Validation01:15

Data Validation

3.3K
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
3.3K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

30
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of continuous renal replacement therapy efficacy in severe caffeine intoxication: concentration-dependent variation in caffeine clearance.

CEN case reports·2026
Same author

Ganoderic Acid A Derived from Reishi Mushroom Ganoderma lucidum Protects against Intestinal Immunity Reduction Due to Oxidative Stress in Rat.

Biological & pharmaceutical bulletin·2026
Same author

Impact of time to antibiotic optimization following inadequate or excessive empiric therapy on clinical outcomes.

Infection control and hospital epidemiology·2026
Same author

A study of "Doctor Heli" air ambulance utilization and perinatal outcomes in Fukushima Prefecture, Japan.

Fukushima journal of medical science·2026
Same author

Guideline impact on antibiotic use for tooth extraction across facility types in Japan: an interrupted time series analysis using a health insurance claims database.

The Journal of hospital infection·2026
Same author

Insights from wastewater surveillance into testing-related underreporting and hospital-acquired SARS-CoV-2 infections.

Environment international·2026

Related Experiment Video

Updated: Feb 23, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Validating the Effectiveness of Switching the Vancomycin TDM Analysis Software Based on the Predictive Accuracy.

Shungo Imai1, Takehiro Yamada1, Nobuhisa Ishiguro2

  • 1Department of Pharmacy, Hokkaido University Hospital.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|September 5, 2017
PubMed
Summary

Switching vancomycin (VCM) therapeutic drug monitoring (TDM) software improved VCM dose setting. The new SHIONOGI-VCM-TDM software increased achieving therapeutic VCM levels by 21.6% compared to the older MEEK software.

Keywords:
initial dose settingstherapeutic drug monitoringvancomycin

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

29.9K

Related Experiment Videos

Last Updated: Feb 23, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K
A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

29.9K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Monitoring

Background:

  • Therapeutic drug monitoring (TDM) is crucial for optimizing vancomycin (VCM) dosing.
  • Previous predictive performance analysis led to a software change for VCM TDM analysis.

Purpose of the Study:

  • To validate the effectiveness of switching VCM TDM analysis software for initial VCM dose setting.
  • To compare the rates of achieving therapeutic VCM serum concentrations between two software systems.

Main Methods:

  • A retrospective study comparing two groups of 162 patients each.
  • Patients received VCM with initial doses set by either "Vancomycin MEEK TDM analysis software Ver2.0" (MEEK) or "SHIONOGI-VCM-TDM ver.2009" (VCM-TDM).
  • Serum VCM trough concentrations were analyzed to determine attainment of the therapeutic range (10-20 μg/mL).

Main Results:

  • The VCM-TDM group showed a significantly higher rate of achieving therapeutic VCM levels (64.2%) compared to the MEEK group (42.6%).
  • Switching to VCM-TDM improved the attainment rate by 21.6% (p<0.01).
  • Multivariate analysis identified patient age ≥65, furosemide use, and the VCM-TDM software as independent factors for achieving therapeutic VCM levels.

Conclusions:

  • The change in VCM TDM analysis software from MEEK to VCM-TDM significantly improved the initial dose setting of vancomycin.
  • VCM-TDM is an effective tool for optimizing vancomycin therapy, contributing to better patient outcomes.